Twist Bioscience Co. (NASDAQ:TWST – Get Free Report) CEO Emily M. Leproust sold 13,605 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $43.21, for a total transaction of $587,872.05. Following the sale, the chief executive officer now owns 481,918 shares of the company’s stock, valued at $20,823,676.78. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Twist Bioscience Stock Up 1.3 %
Shares of NASDAQ:TWST opened at $43.34 on Friday. Twist Bioscience Co. has a 12 month low of $14.42 and a 12 month high of $60.90. The company’s 50-day moving average price is $44.94 and its two-hundred day moving average price is $43.69. The firm has a market cap of $2.52 billion, a P/E ratio of -12.90 and a beta of 1.77.
Twist Bioscience (NASDAQ:TWST – Get Free Report) last issued its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The company had revenue of $81.50 million for the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The firm’s revenue was up 27.7% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.01) EPS. As a group, equities analysts predict that Twist Bioscience Co. will post -3.13 earnings per share for the current fiscal year.
Analyst Ratings Changes
View Our Latest Stock Analysis on Twist Bioscience
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. EdgeRock Capital LLC bought a new position in shares of Twist Bioscience in the 2nd quarter valued at about $43,000. Blue Trust Inc. boosted its stake in shares of Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after purchasing an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in shares of Twist Bioscience in the 2nd quarter valued at about $61,000. Nisa Investment Advisors LLC boosted its stake in shares of Twist Bioscience by 31.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock valued at $113,000 after purchasing an additional 546 shares during the last quarter. Finally, CWM LLC boosted its stake in shares of Twist Bioscience by 27.4% in the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after purchasing an additional 524 shares during the last quarter.
Twist Bioscience Company Profile
Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.
Further Reading
- Five stocks we like better than Twist Bioscience
- What is the S&P/TSX Index?
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- How to Calculate Options Profits
- MarketBeat Week in Review – 9/30 – 10/4
- Why Are These Companies Considered Blue Chips?
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.